METRIOPHARM

MetrioPharm is a clinical-stage company at the forefront of developing safer and more effective treatments based on first-in-class self-regulating immunomodulators for inflammatory and infectious diseases. MetrioPharm has developed a platform of oral small molecule immune modulators that target the pathologically dysregulated (reprogrammed) mitochondrial metabolism in macrophages and other immune cells without being immunosuppressive... MetrioPharm AG is a private, clinical-stage biotech company focused on therapies for inflammatory and infectious diseases. The company is headquartered in Zurich and has a subsidiary for R&D activities in Berlin.

Also known as: MetrioPharm AG, MetrioPharm Deutschland GmbH, MetrioPharm Germany GmbH

Registration numbers: CHE-109.856.841 (W), HRB 174128 B (W)

VAT numbers: DE282232503

Primary location: Zurich